Furthermore, SAMD4B facilitates breast cancer cell cycle progression through the downregulation of p53 and p21, and the concomitant upregulation of Cyclin E-CDK2 and Cyclin D1-CDK4 complexes, thereby driving the G1/S phase transition. Here, TP53 is linked to breast carcinoma.